Swiss drugmaker Roche raised its 2019 outlook after first-quarter sales beat analyst forecasts on the strength of newer medicines including multiple sclerosis treatment Ocrevus and cancer immunotherapy Tecentriq.
from Reuters: Company News https://reut.rs/2Xi1pny
via IFTTT
from Reuters: Company News https://reut.rs/2Xi1pny
via IFTTT
إرسال تعليق